The joint venture will manufacture and sale an algae-based product intended to provide an alternative for other sources of Omega-3 fatty acids for the production of animal feed. Both Evonik and DSM are specialty chemical companies active -amongst others- in animal nutrition.
The Commission concluded that the proposed transaction would raise no competition concerns because the expected activities and turnover of the joint venture in the EEA are limited.
The transaction was examined under the simplified merger review procedure. More information is available on the Commission's competition website, in the public case register under the case number M.8514.
